1
|
Timmerman P, Barfield M, Cowan K, Golob M, Goodman J, Kunz U, Laurén A, Love I, Nelson R, Staack RF, Stanta J, van de Merbel N, Wilson A. Recommendations and discussion points on immunogenicity, biomarkers, automation/technology and protein-MS from the 2021 European Bioanalysis Forum Focus Workshops. Bioanalysis 2021; 13:1459-1465. [PMID: 34605275 DOI: 10.4155/bio-2021-0200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Accepted: 09/15/2021] [Indexed: 01/15/2023] Open
Abstract
During the first half of 2021, and due to the SARS-CoV-2 pandemic preventing in-person meetings, the European Bioanalysis Forum organized four workshops as live interactive online meetings. The themes discussed at the workshops were carefully selected to match the cyberspace dynamics of the meeting format. The first workshop was a training day on challenges related to immunogenicity. The second one focused on biomarkers and continued the important discussion on integrating the principles of Context of Use (CoU) in biomarker research. The third workshop was dedicated to technology, that is, cutting-edge development in cell-based and ligand-binding assays and automation strategies. The fourth was on progress and the continued scientific and regulatory challenges related to peptide and protein analysis with MS. In all four workshops, the European Bioanalysis Forum included a mixture of scientific and regulatory themes, while reminding the audience of important strategic aspects and our responsibility toward the patient.
Collapse
Affiliation(s)
| | - Matthew Barfield
- Roche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Kyra Cowan
- Merck KGaA, New Biological Entities Drug Metabolism & Pharmacokinetics, 64293, Darmstadt, Germany
| | | | - Joanne Goodman
- Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, UK
| | - Ulrich Kunz
- Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, 88400, Biberach ad Riss, Germany
| | - Anna Laurén
- Non-clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Novo Nordisk A/S, DK-2760, Måløv, Denmark
| | - Iain Love
- Charles River Laboratories, Department of Chromatographic Bioanalysis, EH33 2NE, Edinburgh, UK
| | - Robert Nelson
- Labcorp Drug Development, Scientific Affairs, 1217, Meyrin, Switzerland
| | - Roland F Staack
- Roche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, 82377, Penzberg, Germany
| | - Johannes Stanta
- Freeline Therapeutics, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, SG1 2FX, UK
| | | | - Amanda Wilson
- Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB22 3AT, UK
| |
Collapse
|
2
|
Special Focus Issue - COVID-19: bioanalytical considerations, contributions and lessons - part 1. Bioanalysis 2021; 13:1157-1159. [PMID: 34404225 DOI: 10.4155/bio-2021-0168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|